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Loxapine is an antipsychotic used in psychiatry for over 40 years with a well-established profile. Loxapine is a
dibenzoxazepine tricyclic antipsychotic agent, available for oral, intramuscular and inhalatory administration. In
the light of the recent approval by the regulatory agencies of inhaled loxapine for use in the acute treatment of
mild-to-moderate agitation in adults affected with schizophrenia or bipolar disorder, this article aims to critically
review the available literature on loxapine, irrespective of its formulation.
This review examines the efficacy and tolerability of the various formulations of loxapine in the treatment of agitation
and aggression in patients affected with schizophrenia, bipolar disorder and other psychiatric conditions.
A comprehensive and systematic literature search of PubMed/MEDLINE was conducted, and relevant
pharmacodynamic and pharmacokinetic data was included. The findings from the literature were critically reviewed
and synthesized.
The available data suggests that the antipsychotic efficacy of loxapine is similar to the efficacy of other typical or
atypical antipsychotics, with an adverse effects profile comparable to that of the typical antipsychotics at high doses for
chronic treatment. As an acute treatment in agitation associated with schizophrenia or bipolar disorder, inhaled
loxapine was developed as an innovative and rapid option which appears to be efficacious and tolerable.
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Loxapine, an antipsychotic that has striking similarities
to clozapine, has been recently re-launched as a treat-
ment for agitation in schizophrenia and mania. Acute
agitation, characterized by motor restlessness and mental
tension, is a serious medical problem that may be present
in various psychiatric disorders, including schizophrenia
[1] and bipolar disorder [2] and can further escalate into
aggressive behaviour [3]. It is important to identify agita-
tion early in its course during its mild stages and achieve
results quickly in order to prevent the escalation to ag-
gressive or violent behaviour into more severe stages. In
addition to the timely pharmacological treatment, acute
interventions that target agitation usually also involve en-
vironmental and behavioural approaches [3]. Acute agita-
tion requires prompt intervention to reduce the risk of
patient injury and distress and to ensure the safety of
other individuals (such as hospital staff, other patients,
family members) [4].* Correspondence: evieta@clinic.ub.es
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unless otherwise stated.The first attempts to treat agitation pharmacologically
began with methylene blue, when Paul Erlich found that,
when injected into frogs, it selectively stained nerve cells
[5]. In 1899, Pietro Bodoni reported on its use to treat
psychotic disturbances, in particular to calm psychotic
agitation. In addition to morphine and scopolamine
(hyoscine) combinations, barbiturates were main agents
utilized to cure agitation until Delay and Deniker tested
chlorpromazine. This compound was noted to be able to
calm the agitation of patients with delirium, mania and
psychosis even in monotherapy [5,6]. This observation
was followed by numerous others, and the effectiveness
of chlorpromazine in the treatment of agitated, over-
active and manic states was widely confirmed [7,8].
Emergency sedation for behavioural disturbance in
psychiatry in the mid-twentieth century, termed “rapid
tranquillization”, received increasing attention after the
arrival of antipsychotic drugs, which replaced older seda-
tives and became the agents most strongly associated
with the treatment of aggression and challenging behav-
iour [9-11].
The mental health system was profoundly transformed
by the use of antipsychotics. In the 1960s, the use of thisl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ment to outpatient clinics, community mental centres
and mental hospitals. One of these compounds, loxa-
pine, has been used for the treatment of schizophrenia
since the mid-1970s [12,13] and is nowadays quite
widely used in countries like France or Canada. In the
light of the recent approval by the regulatory agencies of
loxapine inhalation powder (ADASUVE®) in the USA
and the EU for use in the acute treatment of agitation in
adult patients with schizophrenia or bipolar disorder
[4,14], this article aims to critically review the available
literature on loxapine irrespective of its formulations.Methods
A comprehensive and systematic literature search of all
the articles on MEDLINE and PubMed, published up to
March 2014 was performed, using the search term “loxa-
pine” cross-referenced with “oral”, “bipolar disorder”,
“schizophrenia”, “agitation” and/or “randomized con-
trolled trial”. The search was supplemented by manually
reviewing reference lists from the identified publications.
The search included articles in English, Spanish, German
and French. Relevant findings were then identified and
synthesized in combination with additional literature re-
garding the pharmacodynamic and pharmacokinetic
data. A general scheme of the output generated by the
search is shown in Figure 1.Figure 1 Flow diagram of study design and results.Results
Mechanism of action of loxapine
Loxapine is a dibenzoxazepine tricyclic antipsychotic
agent, its chemical structure is similar to clozapine [13]
(Figure 2) and is available for oral, intramuscular [13]
and, following recent approval, inhalatory route [5].
The efficacy of loxapine is proposed to be mediated
through high-affinity antagonism of postsynaptic dopa-
mine D2 receptors and serotonin 5-HT2A receptors
[15]. Although classified as a typical antipsychotic, loxa-
pine has atypical characteristics. When antipsychotics
are classified as typical or atypical, several considerations
need to be kept in mind, including propensity for or lack
of motor side effects such as extrapyramidal side effects
and tardive dyskinesia and efficacy in treatment of nega-
tive symptoms.
The pharmacokinetic and pharmacodynamics proper-
ties of loxapine in favour of its atypical characteristics
are the following:
– Receptor binding, especially at dopamine-2 (D2)
serotonin-2A (5-HT2A) receptors and its high 5-
HT2/D2 ratio, which is more characteristic of atyp-
ical antipsychotics [16-18]. Loxapine has a similar
binding affinity as clozapine and olanzapine with a
more potent 5-HT2A antagonism.
– Receptor occupancy: antipsychotic blockade of at
least 60% of D2 R in the striatum is necessary for
Figure 2 Chemical structure of loxapine, amoxapine, clozapine, quetiapine and olanzapine.
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more of D2 are blocked, EPS are likely to occur.
Loxapine at 10–100 mg/day was found to be
equipotent at blocking D2 and 5-HT2A receptors
[19]. Positron emission tomography imaging re-
vealed D2 receptor occupancy ranging from 43% to
90% and 5-HT2A receptor occupancy ranging from
27% to >98%; the loxapine dosage required to oc-
cupy 50% of D2 and 5-HT2A receptors was 9.6 and
13.6 mg/day, respectively [19]. Loxapine presents
intermediate dissociation from the dopaminergic re-
ceptors, identical to olanzapine [20].
– Regarding affinity of other receptors, loxapine binds
with higher affinity to D4 receptors than the other
dopaminergic receptors, similarly to clozapine
[13,21]. Additionally, loxapine has a higher affinity
for D3 than D2 receptors [22].
– Antagonism of additional receptors: loxapine binds
to noradrenergic, histaminergic H1 and cholinergic
M1 receptors [13,23] (Table 1). Its interaction with
these systems may influence the spectrum of its
pharmacological effects that are associated with
calming effects and suppression of aggressive
behaviour.
The pharmacokinetic characteristics of loxapine are listed
in Table 2. Metabolism of loxapine includes demethylationTable 1 Relative affinities of loxapine for various
neurotransmitter receptors
D1 D2 D3 D4 H1 M1 ά1 ά2 5-HT 1 5-HT 2
Loxapine ++ +++ +++ +++ ++ + ++ − − +++
+++ Very high, ++ high, + moderate, − low.to its primary N-demethylated metabolite amoxapine, a
tricyclic antidepressant. The cytochrome P450 (CYP)
enzyme CYP1A2 is involved in the hydroxylation of
loxapine to 8-OH-loxapine, and CYP3A4 and CYP2D6
are involved in its hydroxylation to 7-OH-loxapine
[10,13,24]. Loxapine also undergoes N-oxidation by fla-
vonoid monoamine oxidases to form loxapine N-oxide
and de-methylation by CYP3A4, CYP2C19 and CYP2C8
to form amoxapine. 8-OH-loxapine has no pharmaco-
logical activity at the D2 receptor, although 7-OH-
loxapine (a minor metabolite) binds to D2 receptors with
high affinity [10,13].Efficacy and tolerability of loxapine
The efficacy and tolerability of loxapine were well estab-
lished through its large period of use not only in chronic
and continuous treatment for schizophrenia or other
psychiatric conditions [22] but also in acute psychotic
stages.The use of loxapine in schizophrenia
A 2007 Cochrane review included 41 studies, comparing
loxapine to haloperidol, thiothixene, risperidone, cloza-
pine and quetiapine [22]. As emerging from the review,
compared with placebo, loxapine has an antipsychotic
effect, based on the results of two randomized controlled
trials (RCT), with a number needed to treat (NNT) of 3
[CI 3–5]. It is as effective as typical drugs in the short
term (4–12 weeks) according to 13 RCTs. Very limited
heterogeneous data suggest that, given intramuscularly
(IM), loxapine may be at least as sedating as IM halo-
peridol and thiothixene [22].
Table 2 Pharmacokinetic parameters of loxapine
pKa 6.6
Half-life
Route oral 4 h (range 1–14)
Intramuscular 12 h (range 8–23)
Inhalatory route 4 h (range 6–8)
Time to peak concentration
Route oral 1 h
Intramuscular 5 h
Inhalatory route 2 min (1–3)
Metabolites 7- and 8-Hydroxyloxapine
Desmethyl-loxapine (amoxapine)
7- and 8-Hydroxyamoxapine
Ioxapine N-oxide
Excretion Excretion of glucuronide conjugates
in urine
Unchanged in faeces
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was also found as effective as atypicals (risperidone, que-
tiapine) and typicals such as perphenazine [25] and tri-
fluoperazine [26] in small, head to-head trials [27]. The
trial characteristics of the included trials are described in
Additional file 1.
Regarding the tolerability of loxapine, common side ef-
fects of oral loxapine include parkinsonian-like symptoms
such as tremor, hypomimia, rigidity, akathisia, drowsiness,
dry mouth, constipation and weight changes [27].
According to a population-based cohort study of eld-
erly people, the risk of death associated with conven-
tional antipsychotic medications is comparable to and
possibly greater than the risk of death associated with
atypical antipsychotic medications [28]. In comparison
with risperidone, haloperidol was associated with the
greatest increase in mortality (mortality ratio 2.14, 95%
CI 1.86–2.45) and loxapine, the lowest (mortality ratio
1.29, 95% CI 1.19–1.40) [29].
To date, no definitive association has been found be-
tween the use of antipsychotics during pregnancy and an
increased risk of birth defects or other adverse outcomes.
There are no studies concerning loxapine use in preg-
nancy in the literature, and the manufacturer reports out-
comes from only three pregnancies with loxapine
exposure: one child born with achondroplasia, one child
born with multiple unspecified malformations and one
child with tremors at 15 weeks of age [30]. However, the
retrospective nature of these reports does not permit to
reach conclusions regarding the safety of this drug in
pregnancy. Overall, there is a paucity of information, with
a lack of large, well-designed, prospective comparative
studies on the safety of antipsychotics in pregnancy [30].The use of loxapine in bipolar mania
Acute mania frequently constitutes a medical emergency,
requiring prompt intervention to avoid destructive and
possibly life-endangering behaviour [31]. Although it is
evident that patients with acute bipolar mania require
rapid and effective treatments that safely control this dan-
gerous process [32], there is a paucity of empirical data re-
garding speed of action of antimanic treatments, an
extremely important issue in clinical practice [33]. As
shown in a recent meta-analysis, haloperidol has a faster
onset of antimanic action than second-generation antipsy-
chotics [33] although it also carries greater risk of switch
into depression [34].
Chlorpromazine and haloperidol are the most studied
typical antipsychotics in the treatment of bipolar mania
[35]. One small placebo-controlled study supports the
efficacy of chlorpromazine [36] while several studies
support the efficacy of haloperidol in this indication.
The first publications date back to 1975 [24], while more
recent studies support the efficacy of up to 30 mg/day of
haloperidol for the treatment of acute mania, with a re-
sponse rate vs. placebo at 3 weeks of 47–56.1% vs. 20–
35%, respectively [37-41]. To date, there have been no
trials assessing the efficacy of the oral or intramuscular
formulation of loxapine in acute treatment of manic epi-
sode. One RCT found inhaled loxapine effective in the
reduction of agitation as early as 10 min after first ad-
ministration in bipolar patients in manic or mixed epi-
sode [42]. Typical antipsychotics such as haloperidol,
zuclopenthixol or loxapine are still widely prescribed in
the treatment of mania, due to the need to acquire ad-
equate and rapid sedation or even the so-called chemical
containment [43]. However, the treatment with typical
antipsychotics carries a potential risk and associated side
effects such as extrapyramidal side effects, depressogenic
effect and malignant syndrome [43]. It is noteworthy
that some authors have established that the patients af-
fected with mood disorders are more prone to develop
extrapyramidal side effects than the schizophrenic pa-
tients [44,45], which may contribute to limit the pre-
scription of typical antipsychotics in this population
beyond punctual administration.
Loxapine in the treatment of agitation across psychiatric
disorders
Timely treatment of agitation is essential, also considering
that it can further escalate into aggressive behaviour. Ag-
gressive behaviour is variable in intensity and targets with
a wide range of expression either verbal, against objects,
self or other persons (frequently called violence) [3].
Reports evaluating loxapine’s effects date back to the
1970s. Five small-scale, randomized, double-blind trials
studies assessed the relationship between loxapine treat-
ment and aggression [46-50]. Whatsoever, the small sample
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generalisability of the findings.
Although data supports the use of haloperidol as an effi-
cacious treatment of aggression in autistic disorder
[51-54], the empirical data is less clear regarding the utility
of the other typical antipsychotics in this patient popula-
tion. Only anecdotic reports suggest anti-aggressive effects
of loxapine [55] and amoxapine in autistic children [56],
but there is a clear need for additional research in autistic
and other psychiatric populations.
Recently, inhaled loxapine (ADASUVE) has been ap-
proved by the Food and Drug Administration and Euro-
pean Medical Agency for the acute treatment of agitation
associated with schizophrenia or bipolar disorder in
adults. The approval was based on one phase II and two
phase III efficacy trials in the treatment of acute agitation
in the above-mentioned disorders [42,57,58]. In two phase
III studies (one in subjects with schizophrenia, the other
in subjects with bipolar disorder) inhaled loxapine doses
of 5 and 10 mg were both superior to placebo 10 min after
administration. Pooled data from these three efficacy stud-
ies suggest a NNT for response of 4 (95% CI 3–5) and 3
(95% CI 3–4) for inhaled loxapine (5 or 10 mg vs. placebo)
for agitation associated with schizophrenia or bipolar dis-
order, respectively. These values are in the range with ef-
fect size observed for intramuscular administration of
other antipsychotics [59].
According to data pooled from the three existing effi-
cacy studies of inhaled loxapine, no clinically relevant
extrapyramidal side effects or akathisia have emerged
following administration of loxapine 10 mg or 5 mg, and
the most commonly encountered adverse event was
short-term dysgeusia, with a number needed to harm vs.
placebo of 10 (95% CI 7–22) or 12 (95% CI 8–26), re-
spectively [59]. Given that the route of administration is
inhalation, active airways disease (asthma and chronic
obstructive pulmonary disease) are contraindicated due
to the risk of bronchospasm [27]. There is no apparent
QT prolongation associated with the therapeutic dose of
inhaled loxapine [60].
Discussion
The present review of the available literature derives from
the large experience of 40 years of loxapine use in chronic
treatment of psychiatric disorders and their agitated stages.
The systematic Cochrane review assessing all random-
ized controlled trials that compared loxapine (in dosages
up to 300 mg/day) to other chronic treatments in
schizophrenia concluded that loxapine was not distinct
from typical or atypical drugs in terms of its effects on
global or mental state and exhibited a similar adverse ef-
fect profile to typical antipsychotics but may cause more
extrapyramidal adverse effects when compared with
atypical antipsychotics [22].Furthermore, loxapine is more effective than other
‘typical’ antipsychotics in reducing the negative symp-
toms of schizophrenia [57]. Extrapyramidal side effects
are not usually observed at clinically effective anti-
psychotic doses [61]. Loxapine, although classified as a
conventional antipsychotic, at low doses (<50 mg/day)
may be considered as an atypical one [13,18].
Considering the above-mentioned data, and with the
aim of improving the treatment of agitated patients with
schizophrenia and bipolar disorder [62], inhaled loxapine
was developed and approved as an effective and toler-
able option. This innovative approach could be a good
option in the management of agitation, intercepting the
escalation to its severe stages.
Existing evidence supports the efficacy of clozapine in
reducing suicidal behaviour in patients with schizophre-
nia [63-68]. In view of the similarities between clozapine
and loxapine, future studies should investigate potential
anti-suicidal properties of loxapine.
Conclusions
Data suggests that loxapine is an antipsychotic drug
with an efficacy similar to other typical or atypical
agents in terms of antipsychotic efficacy and adverse ef-
fects profile similar to that of the typical antipsychotics
at high doses for the chronic treatment. As an acute
treatment of agitation associated with schizophrenia or
bipolar disorder, inhaled loxapine, as delivered through
a fast-heating device (Staccato), was developed as an in-
novative and particularly rapid pharmacological option
which appears to be efficacious and tolerable in most
clinical settings where psychiatric agitation is problematic.
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